SAS PROC GLM with group effect [General Sta­tis­tics]

posted by Silva – Portugal, 2014-05-23 14:12 (4403 d 20:35 ago) – Posting: # 12992
Views: 17,080

Thanks for all the input.

From all the discussions about group effect within the forum, a thought came to me? Do we really need to test Group effect? If not tested, what happens is the increase of MS error and therefore CI's are expected to be widened, which increases Producer's risk! Does FDA or EMA really ask for group effect?

For Bioequivalence statistics (ANOVA and CI's calculation), is it Phoenix so acceptable as SAS for FDA? And for EMA?

Rgs
Silva


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
138 visitors (0 registered, 138 guests [including 41 identified bots]).
Forum time: 10:48 CEST (Europe/Vienna)

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5